rss
Gut doi:10.1136/gutjnl-2012-302019
  • PostScript
  • Letter

IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5

  1. Francesco Negro8
  1. 1Department of Gastroenterology, Saint Louis Hospital, Ismailiye, Aleppo, Syria
  2. 2Service of Infectious Diseases, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
  3. 3Laboratory Medicine, Saint Louis Hospital, Ismailiye, Aleppo, Syria
  4. 4Department of Internal Medicine, Squelbiye National Hospital, Squelbiye, Syria
  5. 5Department of Gastroenterology, Damascus Hospital, Damascus, Syria
  6. 6Department of Gastroenterology, Ibn Nafis Hospital, Damascus, Syria
  7. 7Department of Laboratory Medicine, Damascus Hospital, Damascus, Syria
  8. 8Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Genève, Switzerland
  1. Correspondence to Professor Francesco Negro, Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, 4 rue Gabrielle-Perret-Gentil, CH-1211 Geneva 14, Switzerland; francesco.negro{at}hcuge.ch
  1. Contributors NA, KK, FA, OB, SA, MH, DA and HS contributed patient samples and performed all analyses other than genetic tests; SB performed all genetic analyses; NA, P-YB and FN analysed the data and wrote the manuscript; All authors approved the manuscript.

  • Accepted 12 January 2012
  • Published Online First 16 February 2012

We read with interest the paper by Hayes et al1 on the impact of genetic polymorphisms near IL28B in predicting treatment response in chronic hepatitis C patients infected with hepatitis C virus genotype 1 (HCV-1). These results confirm the large, existing evidence in support of single nucleotide polymorphisms (SNPs) near IL28B being the most powerful predictors of virological response in patients infected with all major HCV genotypes, that is, 1–4.2 No data is available for HCV-5, a rare genotype neglected in clinical trials.3 We report IL28B SNP frequency and its impact on treatment outcome in 49 patients of homogeneous Caucasian ancestry, all from Syria, infected with HCV-5. Treatment included …


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Gut.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article